NovaSAID AB is a Swedish research company developing drugs for diseases associated with inflammation, pain and fever such as Rheumatoid Arthritis and Osteoarthritis.

The company’s objective is to develop innovative small-molecule compounds that inhibit the mPGES-1 enzyme. mPGES-1 is linked to several pathological conditions, e.g. chronic and acute inflammation, pain, fever, anorexia, atherosclerosis, stroke and cancer.

The company’s goal is to develop a new generation of NSAIDs to the point of clinical proof of concept. The company is open to strategic partnership or project licensing discussions.